The balloon-expandable valve is already approved for use in India and Europe. New data presented at EuroPCR 2024 in Paris compared it to contemporary devices seen by many as the gold standard for TAVR care. 

The new algorithm from Implicity evaluates implantable device data and monitors patients for changes that suggest they could experience severe heart failure symptoms in the near future. It was designed to alert clinicians up to weeks in advance.

One of the biggest decisions in a cardiologist's life is knowing when, exactly, to start a family. Nandita S. Scott, MD, co-director of the Corrigan Women's Heart Health Program at Mass General Hospital, shared her perspective on this important topic. 

Researchers tracked data from more than 600 patients, noting that heart teams may want to reconsider how they classify residual TR after treatment. 

HeartFlow's noninvasive Plaque Analysis technology, which uses AI to evaluate CCTA images, delivered assessments that mostly lined up with IVUS results. 

Atraverse Medical, a San Diego-based medical device company founded in 2022, designed the guidewire to give physicians as much freedom as possible while treating heart patients. 

The supra-annular AltaValve System was designed to treat both primary and secondary mitral regurgitation. It is implanted via transseptal access and positioned above the native mitral valve.

Researchers tracked data from more than 7,500 patients, sharing their findings at EuroPCR 2024 in Paris and in JSCAI.

Abbott issued the new recall after receiving more than 80 reports of blood or air entering the LVAD during implant procedures. Customers can still use these devices, but they are advised to follow specific steps to limit the risk of complications. 

The group wants countries to implement population-wide changes that can keep salt intake to a minimum. It estimates that such policies could save up to 900,000 lives in just a few years.